Neuralink last year received the US Food and Drugs Administration (FDA) approval for human trials and said in September it was looking for its first test subjects for the six-year initial trial.
If the US Food and Drugs Administration (FDA) authorises the kid-size Covid-19 vaccination doses now, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.